It has been about a month since the last earnings report for Johnson & Johnson (JNJ). Shares have lost about 6.7% in that time frame, underperforming the S&P 500. Will the recent negative trend ...
GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback